metabolic drugs

Illustration of the concept of layoff and downsizing of staff
Biotech

Biomea cuts staff, drops leukemia asset in metabolic shift

Biomea is homing in on lead asset icovamenib, a menin inhibitor designed to address the underlying cause of diabetes, and a preclinical GLP-1 agonist.
Darren Incorvaia May 5, 2025 6:59pm
deal handshake biotech deal pharma deal biopharma deal

Novo taps Photys for multi-molecule cardiometabolic collab

Dec 18, 2024 7:30am
proclaim red announcement

Aligos MASH prospect slashes liver fat in phase 2

Sep 19, 2024 1:00pm
close-up image of an eye

Skye ends eye disease R&D after glaucoma drug's phase 2 fail

Jun 10, 2024 8:51am
liver disease fibrosis NASH NAFLD cancer cirrhosis liver

Chinese biotech's MASH drug reduces liver fat in phase 2 trial

Mar 18, 2024 11:07am
Anti-obesity medication in a tiny shopping cart

Lindus hops on GLP-1 hype with CRO service for metabolic disease

Mar 6, 2024 12:45pm